AMRI to be Acquired by The Carlyle Group
The company will be acquired for $21.75 per share in cash.
On June 6, 2017, AMRI announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group for $21.75 per share in cash. The agreement was unanimously approved by AMRI's Board of Directors, which has recommended that the shareholders vote in favor of the transaction.
Closing of the transaction is subject to customary closing conditions. It is anticipated that the special meeting of AMRI's stockholders to vote on the transaction will be held in the third quarter of 2017, and if the transaction is approved, the merger would be expected to close shortly thereafter.
Source: AMRI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
